SanBio Co Ltd (TSE:4592)
円 775 100 (14.81%) Market Cap: 53.19 Bil Enterprise Value: 49.83 Bil PE Ratio: 0 PB Ratio: 19.30 GF Score: 35/100

Q2 2021 SanBio Co Ltd Earnings Call Transcript

Sep 15, 2020 / NTS GMT
Release Date Price: 円1792 (+20.11%)
Keita Mori
SanBio Company Limited - Co-Founder, President, Executive Officer & Representative Director

So good afternoon. Thank you very much for coming to this update meeting today. My name is Keita Mori, CEO of SanBio. As you can see, we have a number of topics today, so I'd like to go straight into the subject today.

So first, a brief update on the finance results. First, I'd like to go over the income statement. As we are product development stage, R&D cost is the important factor for our business. And as you can see, our R&D costs fell by about $2 million year-to-year due to lower clinical churn expense despite the rise in the manufacturing-related expense. But as you see, overall, it's about $20 million last year, and this is about $18 million this year. So overall, the spending is about the same, and we continue to proactively conduct development to increase the value of our products and the company.

Now going to the balance sheet. Here, the important aspect is the cash. And in the last 6 months, with the spend, we have a decrease of about $27 million equivalent. However

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot